Marc Tessier-Lavigne

Marc Tessier-Lavigne is a declared insider at 5 companies (board member); the most frequent names are Regeneron Pharmaceuticals, Inc., Denali Therapeutics Inc. and Genentech Inc. We count 151 filings; the first trade dates from 16 July 2008 and the latest from 3 June 2025.

On the open market, the record shows 1 purchase worth €758k and 101 sales worth €82.3M. The net balance comes to €81.5M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 12 share grants and 27 option exercises.

The latest filing, published on 5 June 2025, reports a share grant in Denali Therapeutics Inc. The latest purchase dates back some time: it was published 4,586 days ago, on 3 April 2014. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.